Concepts (299)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sjogren's Syndrome | 21 | 2022 | 256 | 7.540 |
Why?
|
| Autoantibodies | 24 | 2022 | 466 | 3.330 |
Why?
|
| Salivary Glands | 7 | 2022 | 51 | 3.200 |
Why?
|
| Ribonucleoproteins | 12 | 2018 | 152 | 2.820 |
Why?
|
| Lupus Erythematosus, Systemic | 15 | 2021 | 986 | 2.410 |
Why?
|
| Antibodies, Antinuclear | 12 | 2021 | 181 | 2.180 |
Why?
|
| Sialadenitis | 5 | 2019 | 16 | 2.030 |
Why?
|
| Mice | 44 | 2022 | 4406 | 1.780 |
Why?
|
| Immunity, Innate | 8 | 2020 | 205 | 1.760 |
Why?
|
| Immunoglobulin G | 7 | 2022 | 266 | 1.660 |
Why?
|
| Disease Models, Animal | 15 | 2020 | 1393 | 1.620 |
Why?
|
| Submandibular Gland | 5 | 2015 | 11 | 1.320 |
Why?
|
| Animals | 50 | 2022 | 9960 | 1.310 |
Why?
|
| Autoantigens | 12 | 2011 | 212 | 1.300 |
Why?
|
| Antibodies, Bacterial | 2 | 2021 | 100 | 1.290 |
Why?
|
| Xerostomia | 2 | 2022 | 9 | 1.220 |
Why?
|
| Salivation | 3 | 2019 | 11 | 1.200 |
Why?
|
| Lupus Nephritis | 7 | 2011 | 99 | 1.150 |
Why?
|
| Autoimmunity | 7 | 2017 | 153 | 1.120 |
Why?
|
| Membrane Proteins | 3 | 2020 | 465 | 1.060 |
Why?
|
| Epitopes | 6 | 2018 | 171 | 1.020 |
Why?
|
| Inflammation | 6 | 2022 | 601 | 1.000 |
Why?
|
| Epitopes, T-Lymphocyte | 4 | 2014 | 45 | 0.860 |
Why?
|
| Female | 34 | 2022 | 14462 | 0.860 |
Why?
|
| Peptides | 5 | 2014 | 280 | 0.850 |
Why?
|
| Intestines | 2 | 2021 | 117 | 0.800 |
Why?
|
| Epitopes, B-Lymphocyte | 5 | 2007 | 24 | 0.770 |
Why?
|
| Immunoglobulin A | 1 | 2021 | 22 | 0.750 |
Why?
|
| Enterococcus | 1 | 2021 | 19 | 0.750 |
Why?
|
| Interferon Type I | 4 | 2020 | 55 | 0.720 |
Why?
|
| Ribonucleoproteins, Small Nuclear | 7 | 2009 | 41 | 0.690 |
Why?
|
| T-Lymphocytes | 6 | 2014 | 273 | 0.680 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2019 | 121 | 0.670 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 121 | 0.650 |
Why?
|
| Lacrimal Apparatus | 2 | 2018 | 3 | 0.650 |
Why?
|
| Autoimmune Diseases | 1 | 2020 | 162 | 0.640 |
Why?
|
| RNA, Small Cytoplasmic | 5 | 2005 | 63 | 0.640 |
Why?
|
| Hyperglycemia | 1 | 2019 | 77 | 0.640 |
Why?
|
| Periodontitis | 1 | 2018 | 11 | 0.620 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2018 | 18 | 0.610 |
Why?
|
| Mice, Inbred NZB | 7 | 2020 | 14 | 0.580 |
Why?
|
| Molecular Mimicry | 2 | 2014 | 30 | 0.550 |
Why?
|
| snRNP Core Proteins | 5 | 2011 | 33 | 0.540 |
Why?
|
| Receptor, Interferon alpha-beta | 2 | 2013 | 7 | 0.530 |
Why?
|
| HLA-DR3 Antigen | 3 | 2014 | 10 | 0.520 |
Why?
|
| Immunization, Passive | 1 | 2015 | 20 | 0.490 |
Why?
|
| Saliva | 5 | 2018 | 94 | 0.480 |
Why?
|
| Antibody Formation | 3 | 2011 | 75 | 0.480 |
Why?
|
| Aluminum | 1 | 2014 | 6 | 0.460 |
Why?
|
| Carrier Proteins | 1 | 2016 | 245 | 0.460 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 445 | 0.460 |
Why?
|
| Mice, Inbred C57BL | 10 | 2020 | 1475 | 0.440 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 3 | 1 | 2013 | 3 | 0.440 |
Why?
|
| Humans | 27 | 2021 | 26826 | 0.440 |
Why?
|
| Interleukin-6 | 2 | 2012 | 189 | 0.430 |
Why?
|
| Toll-Like Receptor 3 | 2 | 2011 | 17 | 0.420 |
Why?
|
| Lymphocyte Activation | 6 | 2014 | 204 | 0.400 |
Why?
|
| Cross Reactions | 7 | 2014 | 65 | 0.400 |
Why?
|
| Calcium Signaling | 1 | 2012 | 68 | 0.390 |
Why?
|
| Peptide Fragments | 3 | 2011 | 197 | 0.390 |
Why?
|
| Mice, Inbred Strains | 4 | 2018 | 61 | 0.390 |
Why?
|
| Antibody Specificity | 4 | 2014 | 113 | 0.350 |
Why?
|
| Genetic Therapy | 1 | 2011 | 116 | 0.340 |
Why?
|
| Interferon-gamma | 3 | 2020 | 102 | 0.340 |
Why?
|
| Genetic Complementation Test | 1 | 2009 | 24 | 0.330 |
Why?
|
| Xanthones | 2 | 2020 | 6 | 0.330 |
Why?
|
| Interferons | 2 | 2020 | 68 | 0.330 |
Why?
|
| Immunization | 5 | 2018 | 118 | 0.330 |
Why?
|
| Hybridomas | 3 | 2014 | 17 | 0.310 |
Why?
|
| Cytokines | 3 | 2019 | 438 | 0.290 |
Why?
|
| Poly I-C | 3 | 2012 | 10 | 0.280 |
Why?
|
| B-Lymphocytes | 4 | 2014 | 275 | 0.280 |
Why?
|
| Mice, Inbred NOD | 3 | 2019 | 49 | 0.270 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2020 | 56 | 0.270 |
Why?
|
| Glomerulonephritis | 4 | 2012 | 16 | 0.260 |
Why?
|
| Mice, Transgenic | 8 | 2011 | 486 | 0.250 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 129 | 0.240 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2011 | 44 | 0.230 |
Why?
|
| Contraception, Immunologic | 2 | 1994 | 4 | 0.230 |
Why?
|
| HLA-DR Antigens | 3 | 2011 | 29 | 0.230 |
Why?
|
| Chorionic Gonadotropin | 2 | 1994 | 22 | 0.230 |
Why?
|
| Amino Acid Sequence | 6 | 2014 | 674 | 0.230 |
Why?
|
| Male | 12 | 2020 | 12869 | 0.230 |
Why?
|
| Kidney Diseases | 3 | 2014 | 59 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2018 | 253 | 0.220 |
Why?
|
| Epitope Mapping | 2 | 2018 | 38 | 0.220 |
Why?
|
| Mesangial Cells | 3 | 2012 | 9 | 0.210 |
Why?
|
| Inhibitor of Differentiation Proteins | 2 | 2014 | 11 | 0.210 |
Why?
|
| Biomarkers | 3 | 2021 | 733 | 0.210 |
Why?
|
| Pilocarpine | 2 | 2014 | 8 | 0.200 |
Why?
|
| Muscarinic Agonists | 2 | 2014 | 9 | 0.200 |
Why?
|
| Rabbits | 1 | 2022 | 272 | 0.200 |
Why?
|
| Adjuvants, Immunologic | 2 | 2014 | 62 | 0.190 |
Why?
|
| Signal Transduction | 3 | 2020 | 1344 | 0.190 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2012 | 100 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 176 | 0.190 |
Why?
|
| Recombinant Proteins | 3 | 2014 | 408 | 0.190 |
Why?
|
| Mice, Knockout | 6 | 2014 | 782 | 0.180 |
Why?
|
| Dacryocystitis | 2 | 2013 | 5 | 0.180 |
Why?
|
| Sarcoidosis | 1 | 2020 | 38 | 0.180 |
Why?
|
| Forkhead Transcription Factors | 2 | 2011 | 34 | 0.180 |
Why?
|
| Models, Animal | 1 | 2020 | 129 | 0.170 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 47 | 0.170 |
Why?
|
| Chemokines | 1 | 2020 | 73 | 0.170 |
Why?
|
| Cell Culture Techniques | 1 | 2020 | 115 | 0.170 |
Why?
|
| Kidney Glomerulus | 2 | 2010 | 15 | 0.170 |
Why?
|
| Endothelial Cells | 1 | 2022 | 324 | 0.170 |
Why?
|
| Monocytes | 1 | 2020 | 132 | 0.170 |
Why?
|
| Immunoprecipitation | 2 | 2017 | 67 | 0.160 |
Why?
|
| Transcriptome | 1 | 2020 | 198 | 0.160 |
Why?
|
| DNA | 5 | 2009 | 365 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2013 | 654 | 0.160 |
Why?
|
| Porphyromonas gingivalis | 1 | 2018 | 6 | 0.160 |
Why?
|
| Treponema denticola | 1 | 2018 | 6 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 439 | 0.150 |
Why?
|
| Sex Factors | 2 | 2018 | 445 | 0.150 |
Why?
|
| Cytosol | 1 | 2018 | 47 | 0.150 |
Why?
|
| Protein Domains | 1 | 2018 | 48 | 0.150 |
Why?
|
| Lung | 1 | 2020 | 349 | 0.150 |
Why?
|
| Mice, Inbred BALB C | 5 | 2012 | 264 | 0.140 |
Why?
|
| Flow Cytometry | 4 | 2011 | 282 | 0.140 |
Why?
|
| Hypergammaglobulinemia | 1 | 2016 | 7 | 0.130 |
Why?
|
| Tripartite Motif Proteins | 1 | 2016 | 8 | 0.130 |
Why?
|
| Sulfur Radioisotopes | 1 | 2016 | 10 | 0.130 |
Why?
|
| Rheumatoid Factor | 1 | 2016 | 28 | 0.130 |
Why?
|
| Gene Expression | 1 | 2018 | 406 | 0.130 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 143 | 0.130 |
Why?
|
| Methionine | 1 | 2016 | 37 | 0.130 |
Why?
|
| Cohort Studies | 1 | 2018 | 857 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2016 | 69 | 0.130 |
Why?
|
| Interleukin-17 | 2 | 2012 | 51 | 0.120 |
Why?
|
| Molecular Sequence Data | 5 | 2005 | 1036 | 0.120 |
Why?
|
| Mice, Mutant Strains | 2 | 2012 | 58 | 0.120 |
Why?
|
| Salivary Glands, Minor | 1 | 2014 | 21 | 0.120 |
Why?
|
| Retrospective Studies | 1 | 2021 | 2433 | 0.120 |
Why?
|
| Capnocytophaga | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2014 | 36 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 54 | 0.110 |
Why?
|
| von Willebrand Factor | 1 | 2014 | 36 | 0.110 |
Why?
|
| Mouth | 1 | 2014 | 29 | 0.110 |
Why?
|
| Vagina | 1 | 2014 | 42 | 0.110 |
Why?
|
| Kidney | 2 | 2012 | 275 | 0.110 |
Why?
|
| Protein Biosynthesis | 2 | 2004 | 106 | 0.110 |
Why?
|
| Skin | 1 | 2014 | 140 | 0.110 |
Why?
|
| Models, Immunological | 3 | 2011 | 22 | 0.100 |
Why?
|
| Antigens | 1 | 2012 | 66 | 0.100 |
Why?
|
| Injections, Intraperitoneal | 1 | 2012 | 34 | 0.100 |
Why?
|
| Immunoglobulin M | 1 | 2012 | 28 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2012 | 68 | 0.100 |
Why?
|
| Submandibular Gland Diseases | 1 | 2011 | 2 | 0.100 |
Why?
|
| Chemokine CCL7 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2011 | 4 | 0.100 |
Why?
|
| Chemokine CCL4 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Vibrio cholerae | 1 | 2011 | 5 | 0.100 |
Why?
|
| Chemokine CCL11 | 1 | 2011 | 3 | 0.100 |
Why?
|
| Chemokines, CC | 1 | 2011 | 3 | 0.100 |
Why?
|
| Chemokine CXCL13 | 1 | 2011 | 7 | 0.100 |
Why?
|
| Th17 Cells | 1 | 2012 | 32 | 0.100 |
Why?
|
| Chemokines, CXC | 1 | 2011 | 12 | 0.100 |
Why?
|
| Chemokine CCL3 | 1 | 2011 | 9 | 0.100 |
Why?
|
| Streptococcus agalactiae | 1 | 2011 | 11 | 0.100 |
Why?
|
| Mice, Inbred A | 2 | 2002 | 14 | 0.100 |
Why?
|
| Leukocytes | 1 | 2012 | 67 | 0.100 |
Why?
|
| Ovalbumin | 1 | 2011 | 7 | 0.100 |
Why?
|
| Chemokine CXCL10 | 1 | 2011 | 22 | 0.100 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2011 | 10 | 0.090 |
Why?
|
| Apolipoproteins E | 1 | 2011 | 44 | 0.090 |
Why?
|
| Chemokine CCL2 | 1 | 2011 | 43 | 0.090 |
Why?
|
| Killer Cells, Natural | 1 | 2011 | 60 | 0.090 |
Why?
|
| Lipids | 2 | 2011 | 195 | 0.090 |
Why?
|
| Glomerular Mesangium | 1 | 2010 | 5 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 262 | 0.090 |
Why?
|
| Middle Aged | 3 | 2017 | 6817 | 0.090 |
Why?
|
| HLA-DQ Antigens | 1 | 2009 | 25 | 0.090 |
Why?
|
| Dendritic Cells | 1 | 2011 | 141 | 0.080 |
Why?
|
| X Chromosome | 1 | 2009 | 6 | 0.080 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 15 | 0.080 |
Why?
|
| Protein Binding | 1 | 2011 | 631 | 0.080 |
Why?
|
| Genes, Dominant | 1 | 2009 | 35 | 0.080 |
Why?
|
| Secretory Rate | 1 | 2009 | 5 | 0.080 |
Why?
|
| Interferon Inducers | 1 | 2009 | 3 | 0.080 |
Why?
|
| Chemokine CCL5 | 1 | 2009 | 3 | 0.080 |
Why?
|
| Salivary Ducts | 1 | 2009 | 3 | 0.080 |
Why?
|
| Integrin alpha Chains | 1 | 2008 | 4 | 0.080 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 42 | 0.080 |
Why?
|
| Freund's Adjuvant | 1 | 2008 | 8 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2008 | 20 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 152 | 0.080 |
Why?
|
| Seminiferous Epithelium | 1 | 2007 | 1 | 0.070 |
Why?
|
| Nuclear Factor 90 Proteins | 1 | 2007 | 1 | 0.070 |
Why?
|
| Nuclear Factor 45 Protein | 1 | 2007 | 1 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2009 | 240 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 453 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 243 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2008 | 134 | 0.070 |
Why?
|
| Muromegalovirus | 1 | 2006 | 1 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2006 | 20 | 0.070 |
Why?
|
| Herpesviridae Infections | 1 | 2006 | 17 | 0.070 |
Why?
|
| Immunologic Memory | 1 | 2007 | 58 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 91 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2006 | 95 | 0.070 |
Why?
|
| Organ Specificity | 2 | 2020 | 81 | 0.070 |
Why?
|
| Homeostasis | 1 | 2007 | 114 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 3 | 2005 | 316 | 0.060 |
Why?
|
| Mutation | 1 | 2009 | 817 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2004 | 57 | 0.060 |
Why?
|
| Lysosomes | 1 | 2004 | 54 | 0.060 |
Why?
|
| Self Tolerance | 1 | 2004 | 9 | 0.060 |
Why?
|
| Nucleosomes | 1 | 2004 | 18 | 0.060 |
Why?
|
| Cell Movement | 2 | 2020 | 353 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 450 | 0.050 |
Why?
|
| Rats | 3 | 2010 | 1545 | 0.050 |
Why?
|
| Immune Sera | 1 | 2002 | 22 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 47 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2002 | 58 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 310 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 130 | 0.050 |
Why?
|
| Clonal Anergy | 1 | 2020 | 11 | 0.050 |
Why?
|
| Antibody Diversity | 2 | 2011 | 4 | 0.050 |
Why?
|
| Immunophenotyping | 1 | 2020 | 58 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2020 | 75 | 0.040 |
Why?
|
| Antigens, Heterophile | 1 | 2000 | 2 | 0.040 |
Why?
|
| Absorption | 1 | 2000 | 14 | 0.040 |
Why?
|
| Crosses, Genetic | 1 | 2000 | 36 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 400 | 0.040 |
Why?
|
| Immunodominant Epitopes | 1 | 1999 | 13 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 1999 | 26 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2020 | 700 | 0.040 |
Why?
|
| Species Specificity | 1 | 1999 | 186 | 0.040 |
Why?
|
| Models, Biological | 1 | 2020 | 446 | 0.040 |
Why?
|
| Vaccination | 1 | 1999 | 167 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 623 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2017 | 24 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2017 | 19 | 0.040 |
Why?
|
| Apoptosis | 1 | 2020 | 739 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 472 | 0.030 |
Why?
|
| Lip | 1 | 2014 | 9 | 0.030 |
Why?
|
| Antibody-Producing Cells | 1 | 2014 | 15 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 747 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2014 | 32 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1994 | 145 | 0.030 |
Why?
|
| Neutralization Tests | 1 | 1993 | 32 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 1993 | 62 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 1993 | 65 | 0.030 |
Why?
|
| Adult | 2 | 2017 | 7382 | 0.030 |
Why?
|
| Cell Line | 1 | 2014 | 672 | 0.030 |
Why?
|
| Isoantigens | 1 | 2012 | 4 | 0.020 |
Why?
|
| CD3 Complex | 1 | 2012 | 23 | 0.020 |
Why?
|
| Th1 Cells | 1 | 2012 | 35 | 0.020 |
Why?
|
| Galactosylceramides | 1 | 2012 | 31 | 0.020 |
Why?
|
| Adaptive Immunity | 1 | 2012 | 37 | 0.020 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2011 | 3 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2011 | 14 | 0.020 |
Why?
|
| Immunologic Techniques | 1 | 2011 | 12 | 0.020 |
Why?
|
| Gene-Environment Interaction | 1 | 2011 | 12 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2011 | 94 | 0.020 |
Why?
|
| Immune System | 1 | 2011 | 29 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2012 | 70 | 0.020 |
Why?
|
| Multiple Organ Failure | 1 | 2011 | 30 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2011 | 49 | 0.020 |
Why?
|
| Transgenes | 1 | 2011 | 59 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2011 | 83 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2012 | 187 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2011 | 134 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2011 | 91 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2014 | 509 | 0.020 |
Why?
|
| Antigens, Nuclear | 1 | 2009 | 22 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 2009 | 6 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2012 | 395 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2010 | 124 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 65 | 0.020 |
Why?
|
| Stochastic Processes | 1 | 2008 | 8 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 216 | 0.020 |
Why?
|
| Antibodies | 1 | 2008 | 124 | 0.020 |
Why?
|
| Haplorhini | 1 | 2007 | 15 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 142 | 0.020 |
Why?
|
| Sequence Alignment | 1 | 2007 | 110 | 0.020 |
Why?
|
| DNA-Binding Proteins | 1 | 2011 | 481 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2007 | 86 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2007 | 33 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 2006 | 17 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2006 | 110 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 58 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 73 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 573 | 0.020 |
Why?
|
| Acute Disease | 1 | 2006 | 153 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 324 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 330 | 0.020 |
Why?
|
| Risk Factors | 1 | 2011 | 2010 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2005 | 130 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2006 | 263 | 0.020 |
Why?
|
| Fas Ligand Protein | 1 | 2004 | 7 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 44 | 0.010 |
Why?
|
| COS Cells | 1 | 2004 | 48 | 0.010 |
Why?
|
| Animals, Congenic | 1 | 2004 | 2 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2004 | 135 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2003 | 132 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2001 | 92 | 0.010 |
Why?
|
| Genotype | 1 | 2001 | 442 | 0.010 |
Why?
|